ClinicalTrials.gg
CompletedNCT00174967Updated Jul 29, 2011Results posted

Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout

A Phase 2 interventional study of Placebo and Febuxostat in Gout, sponsored by Takeda. Completed. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-07-29.

Sponsored by Takeda · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing febuxostat in Gout — 1 open to participants now, 1 under way, none of them phase 3. Febuxostat · Gout.

Enrollment
13th of 29
153 · median 109
Started
2001
with 1 other
Phase 2
9 of 29
none open now
Registered
2nd of 29
by date
Lead sponsor
11 of 29
Takeda

Among the 29 studies testing febuxostat in Gout, this one is the 13th largest by enrollment, is one of 2 that started in 2001, is one of 9 in phase 2, and was the 2nd registered.

Gout

347 studies on the registry are indexed under Gout; 50 are open to participants now.

Browse Gout studies →

Open to participants now

1 of the 29 studies testing febuxostat in Gout is open now. Recruiting first, the newest first:

About febuxostat

Febuxostat: first FDA approval 2009 (ULORIC), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 31 Gout studies recruiting now, 14 (45%) set no upper age limit and 10 (32%) stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing febuxostat in Gout, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), in reducing serum urate levels in subjects with gout.

Read the detailed description

Gout is a chronic urate crystal deposition disorder, which if left untreated may result in progressive disease characterized by joint and bone destruction from tophaceous deposits and renal impairment due to gouty nephropathy. Hyperuricemia, defined as a serum urate concentration of >7.0 milligrams per deciliter (mg/dL), is the underlying metabolic aberration leading to urate crystal deposition in gout. Gout has several clinical presentations, including: recurrent acute attacks of inflammatory arthritis; deposition of monosodium urate monohydrate crystals in joints, bones and even parenchymal organs (tophaceous gout); renal impairment; and uric acid nephrolithiasis. As serum urate levels increase beyond >7.0 mg/dL, the risks for gouty arthritis or for renal calculi increase.

Currently allopurinol is the only xanthine oxidase inhibitor available. Allopurinol is the agent of choice for reduction of serum urate levels in patients with: uric acid overproduction; unresponsive or intolerant to uricosuric agents; impaired renal function; uric acid urolithiasis; or tophi.

Febuxostat (TMX-67) is a non-purine selective xanthine oxidase inhibitor being developed as an orally administered agent for management of hyperuricemia in patients with gout.

03

Conditions studied

  • Gout

Browse trials for

Keywords

  • Uric Acid
  • xanthine oxidase
  • tophi
  • Drug Therapy
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hyperuricemia (serum uric acid ≥8.0 mg/dL).
  • Must meet American College of Rheumatology criteria for gout.
  • Must have adequate renal function (serum creatinine \<1.5 mg/dL).
  • Females of who are sexually active must agree to use adequate , and can neither be pregnant nor lactating from Screening throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • History of xanthinuria
  • Alcohol consumption >14/week
  • Has a history of significant concomitant illness.
  • Has active liver disease.
  • Has a greater than 50 kilogram per meter² (kg/m²)
  • Any other significant medical condition that would interfere with the treatment, safety or compliance with the protocol, as defined by the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Placebo comparator
    Placebo QD

    Drug: Placebo

  • Experimental
    Febuxostat 40 mg QD

    Drug: Febuxostat

  • Experimental
    Febuxostat 80 mg QD

    Drug: Febuxostat

  • Experimental
    Febuxostat 120 mg QD

    Drug: Febuxostat

Interventions

  • DrugPlacebo

    Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.

  • Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.

    Also known as: TMX-67, Tei-6720, Uloric

  • Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.

    Also known as: TMX-67, Tei-6720, Uloric

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.

    Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 28 visit was summarized.

    Time frame: Day 28.

Secondary outcomes

  1. Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.

    Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 7 visit was summarized.

    Time frame: Day 7.

  2. Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.

    Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 14 visit was summarized.

    Time frame: Day 14.

  3. Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.

    Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 21 visit was summarized.

    Time frame: Day 21.

  4. Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.

    Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.

    Time frame: Baseline and Day 7.

  5. Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.

    Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.

    Time frame: Baseline and Day 14.

  6. Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit

    Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.

    Time frame: Baseline and Day 21.

  7. Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.

    Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.

    Time frame: Baseline and Day 28.

  8. Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.

    Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.

    Time frame: Baseline and Any visit (Day 7, 14, 21,or 28)

  9. Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.

    24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.

    Time frame: Baseline and Day 28.

07

Results

Posted Jul 16, 2009

Participant flow

Subjects were enrolled at 24 investigative sites from 31 January 2001 to 9 July 2001

Participant flow — Overall Study
MilestoneFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Started37403838
Completed36373636
Not completed1322
Withdrew: Adverse event1221
Withdrew: Gout flare0001
Withdrew: Other0100

Outcome measures

PrimaryPercentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.

Serum urate values were obtained at the Day 28 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 28 visit was summarized.

Time frame:
Day 28.
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit.5676940
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryPercentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.

Serum urate values were obtained at the Day 7 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 7 visit was summarized.

Time frame:
Day 7.
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 7 Visit.5059913
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryPercentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.

Serum urate values were obtained at the Day 14 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 14 visit was summarized.

Time frame:
Day 14.
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 14 Visit.5668940
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryPercentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.

Serum urate values were obtained at the Day 21 visit. The percentage of subjects whose serum urate decreased to \<6.0 mg/dL at the Day 21 visit was summarized.

Time frame:
Day 21.
Reported as:
Number · percentage of subjects
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.
percentage of subjectsFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 mg/dL at the Day 21 Visit.5976970
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · Fisher Exact · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using Fisher's exact test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryPercent Change in Serum Urate Levels From Baseline to the Day 7 Visit.

Serum urate values were obtained at the Day 7 visit. The percent change in serum urate from baseline to the Day 7 visit was summarized.

Time frame:
Baseline and Day 7.
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percent Change in Serum Urate Levels From Baseline to the Day 7 Visit.-35.0 ± 9.67-39.2 ± 15.9-53.44 ± 12.30.71 ± 12.6
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryPercent Change in Serum Urate Levels From Baseline to the Day 14 Visit.

Serum urate values were obtained at the Day 14 visit. The percent change in serum urate from baseline to the Day 14 visit was summarized.

Time frame:
Baseline and Day 14.
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percent Change in Serum Urate Levels From Baseline to the Day 14 Visit.-37.1 ± 11.70-41.8 ± 14.63-56.9 ± 8.361.62 ± 10.21
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryPercent Change in Serum Urate Levels From Baseline to the Day 21 Visit

Serum urate values were obtained at the Day 21 visit. The percent change in serum urate from baseline to the Day 21 visit was summarized.

Time frame:
Baseline and Day 21.
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percent Change in Serum Urate Levels From Baseline to the Day 21 Visit-37.3 ± 11.30-43.9 ± 16.3-59.4 ± 7.58-0.57 ± 10.63
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryPercent Change in Serum Urate Levels From Baseline to the Day 28 Visit.

Serum urate values were obtained at the Day 28 visit. The percent change in serum urate from baseline to the Day 28 visit was summarized.

Time frame:
Baseline and Day 28.
Reported as:
Mean · percent change from baseline
Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percent Change in Serum Urate Levels From Baseline to the Day 28 Visit.-36.6 ± 12.07-44.3 ± 17.53-59.1 ± 9.92-2.2 ± 12.5
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryMaximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.

Serum urate values were obtained at the Day 7, 14, 21,and 28 visits. The maximum percent change in serum urate levels obtained at any visit was summarized.

Time frame:
Baseline and Any visit (Day 7, 14, 21,or 28)
Reported as:
Mean · percent change from baseline
Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Maximum Percent Change in Serum Urate Level From Baseline During the Entire Treatment Period.42.5 ± 10.0449.2 ± 13.2462.8 ± 7.0510.0 ± 11.12
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
SecondaryPercent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.

24-hour urine uric acid levels were obtained at the Day 28 visit. The percent change in 24-hour urine uric acid level from baseline to the Day 28 visit was summarized.

Time frame:
Baseline and Day 28.
Reported as:
Mean · percent change from baseline
Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.
percent change from baselineFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Percent Change in 24-hour Urine Uric Acid Level From Baseline to Day 28.-43.6 ± 28.9-46.5 ± 27.0-45.7 ± 30.15.9 ± 37.1
Statistical analysis
  • Febuxostat 40 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 80 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)
  • Febuxostat 120 mg QD vs Placebo QD · t-test, 2 sided · p = <0.001 (Pairwise comparisons between placebo and each of the febuxostat treatment groups were performed using a t-test. Adjustment for multiple comparisons was made using Hochberg's procedure.)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Febuxostat 40 mg QD—0/37 (0%)18/37 (48.6%)
Febuxostat 80 mg QD—1/40 (2.5%)19/40 (47.5%)
Febuxostat 120 mg QD—2/38 (5.3%)16/38 (42.1%)
Placebo QD—0/38 (0%)17/38 (44.7%)
Most frequent serious events
Most frequent serious events
EventFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
Suicide AttemptPsychiatric disorders0/370/401/380/38
Back PainGeneral disorders0/370/401/380/38
DeliriumNervous system disorders0/371/400/380/38
Guillian Barre SyndromeNervous system disorders0/371/400/380/38
PneumoniaRespiratory, thoracic and mediastinal disorders0/371/400/380/38
Most frequent other events
Showing 10 of 15
Most frequent other events
EventFebuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QD
DiarrhoeaGastrointestinal disorders1/378/404/384/38
PainGeneral disorders6/373/402/384/38
Back PainGeneral disorders3/372/402/381/38
HeadacheNervous system disorders3/372/402/381/38
Abdominal PainGeneral disorders1/371/402/383/38
RashSkin and subcutaneous tissue disorders0/371/403/380/38
Increased AppetiteGastrointestinal disorders2/370/400/380/38
Liver Function Tests AbnormalInvestigations2/371/401/381/38
ArthralgiaMusculoskeletal and connective tissue disorders2/371/402/380/38
Flu SyndromeGeneral disorders1/370/401/382/38

Baseline characteristics

Age Continuous
Age Continuous(years)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QDTotal
Mean52.2 ± 14.0455.2 ± 13.0956.2 ± 10.8352.4 ± 12.6354.0 ± 12.69
Age, Customized
Age, Customized(participants)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QDTotal
<45 years81071237
45 years to <65 years2119231780
≥65 years8118936
Sex: Female, Male
Sex: Female, Male(Participants)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QDTotal
Female425617
Male33383332136
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QDTotal
White32353432133
Black or African American332311
Hispanic11114
Asian01102
Other10023
Body Mass Index
Body Mass Index(participants)Febuxostat 40 mg QDFebuxostat 80 mg QDFebuxostat 120 mg QDPlacebo QDTotal
≤25 kilogram per meter² (kg/m²)23308
>25 kg/m² to 30 kg/m²1212141351
>30 kg/m² to 35 kg/m²1612121656
>35 kg/m² to 40 kg/m²475622
>40 kg/m²363315
missing00101
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Palo WA, Eustace D, Vernillet L, Joseph-Ridge N. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout. Arthritis Rheum. 2005 Mar;52(3):916-23. doi: 10.1002/art.20935. PubMed 15751090 ↗
  • Colwell HH, Hunt BJ, Pasta DJ, Palo WA, Mathias SD, Joseph-Ridge N. Gout Assessment Questionnaire: Initial results of reliability, validity and responsiveness. Int J Clin Pract. 2006 Oct;60(10):1210-7. doi: 10.1111/j.1742-1241.2006.01104.x. Epub 2006 Aug 15. PubMed 16911575 ↗
  • Goldfarb DS, MacDonald PA, Hunt B, Gunawardhana L. Febuxostat in gout: serum urate response in uric acid overproducers and underexcretors. J Rheumatol. 2011 Jul;38(7):1385-9. doi: 10.3899/jrheum.101156. Epub 2011 May 15. PubMed 21572152 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2001, a primary completion of Jul 2001 and a completion of Jul 2001. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 8 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 15, 2005
Start
Jan 2001
Primary completionActual
Jul 2001
CompletionActual
Jul 2001
Results first posted
Jul 16, 2009
Last update
Jul 29, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00174967
Lead sponsor
Takeda
First posted
Sep 15, 2005
Start date
Jan 2001
Primary completion
Jul 2001
Completion
Jul 2001
Results posted
Jul 16, 2009
Last update
Jul 29, 2011

Study contacts

Medical Director
study chair · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Febuxostat

Start the discussion